As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Nautilus Biotechnology, Inc. The largest reported stake is Parag Mallick's, at 17.6%. 8 filings are on record since March 4, 2026 (Schedule 13D/A, March 4, 2026).
Sell to companies like Nautilus Biotechnology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 4,944,512 · Sole dispositive: 0 · Shared dispositive: 4,944,512 · SCHEDULE 13D/A, 2026-11-03
- · Reporting person: AH Bio Fund II, L.P. · Sole voting: 5,782,188 · Shared voting: 0 · Sole dispositive: 5,782,188 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-09-11
- · Holder: AH Bio Fund II, L.P. · Percent: 6% · SCHEDULE 13D/A
- · Holder: Perceptive Advisors LLC · Percent: 9.1% · SCHEDULE 13D/A
- · Holder: AH Bio Fund II, L.P. · Percent: 7.1% · SCHEDULE 13D/A
Nautilus Biotechnology, Inc. has 8 Schedule 13D or 13G filings on record since 2026-03-04. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 17.6% | 22,557,411 | SCHEDULE 13D/A, 2026-03-04 | 2026-03-02 | |
| 16.3% | 21,249,965 | SCHEDULE 13D/A, 2026-03-04 | 2026-03-02 | |
| AH Bio Fund II, L.P. | 4.9% | 5,782,188 | SCHEDULE 13D/A, 2026-09-11 | 2026-09-09 |
| Perceptive Advisors LLC | 3.9% | 4,944,512 | SCHEDULE 13D/A, 2026-11-03 | 2026-10-05 |
Holding shares or following this stake? See who's behind Nautilus Biotechnology, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Nautilus Biotechnology, Inc. and the records around it.
Nautilus Biotechnology, Inc. elsewhere on the record
Companies that share a holder
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026), Kardigan, Inc. (Oct 2026)
Watch Nautilus Biotechnology, Inc.
Get an email when Nautilus Biotechnology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Nautilus Biotechnology, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Nautilus Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nautilus Biotechnology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| AH Bio Fund II, L.P. | 5,782,188 | 0 | 5,782,188 | 0 | SCHEDULE 13D/A, 2026-09-11 |
| AH Equity Partners Bio II, L.L.C. | 5,782,188 | 0 | 5,782,188 | 0 | SCHEDULE 13D/A, 2026-09-11 |
| Andreessen Horowitz LSV Fund II, L.P. | 481,047 | 0 | 481,047 | 0 | SCHEDULE 13D/A, 2026-09-11 |
| AH Equity Partners LSV II, L.L.C. | 481,047 | 0 | 481,047 | 0 | SCHEDULE 13D/A, 2026-09-11 |
| Marc L. Andreessen | 0 | 6,263,235 | 0 | 6,263,235 | SCHEDULE 13D/A, 2026-09-11 |
| Benjamin A. Horowitz | 0 | 6,263,235 | 0 | 6,263,235 | SCHEDULE 13D/A, 2026-09-11 |
| Perceptive Advisors LLC | 0 | 4,944,512 | 0 | 4,944,512 | SCHEDULE 13D/A, 2026-11-03 |
| Joseph Edelman | 0 | 4,944,512 | 0 | 4,944,512 | SCHEDULE 13D/A, 2026-11-03 |
| Perceptive Life Sciences Master Fund, Ltd. | 0 | 4,778,652 | 0 | 4,778,652 | SCHEDULE 13D/A, 2026-11-03 |
| C2 Life Sciences LLC | 0 | 165,860 | 0 | 165,860 | SCHEDULE 13D/A, 2026-11-03 |
The latest filing identifies Nautilus Biotechnology, Inc. by CUSIP 63909J108 and gives its principal executive office as 2701 Eastlake Avenue East, Seattle, WA 98102 (SCHEDULE 13D/A, 2026-11-03).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-03-04 | Sujal Patel | 16.3% | SCHEDULE 13D/A |
| 2026-03-04 | Parag Mallick | 17.6% | SCHEDULE 13D/A |
| 2026-06-04 | AH Bio Fund II, L.P. | 9.9% | SCHEDULE 13D/A |
| 2026-06-30 | AH Bio Fund II, L.P. | 7.1% | SCHEDULE 13D/A |
| 2026-08-14 | Perceptive Advisors LLC | 9.1% | SCHEDULE 13D/A |
| 2026-08-28 | AH Bio Fund II, L.P. | 6% | SCHEDULE 13D/A |
| 2026-09-11 | AH Bio Fund II, L.P. | 4.9% | SCHEDULE 13D/A |
| 2026-11-03 | Perceptive Advisors LLC | 3.9% | SCHEDULE 13D/A |
Questions about who owns Nautilus Biotechnology, Inc.
Who owns Nautilus Biotechnology, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Nautilus Biotechnology, Inc.: Parag Mallick (17.6%, Schedule 13D/A, filed 2026-03-04) and Sujal Patel (16.3%, Schedule 13D/A, filed 2026-03-04).
Who are the largest shareholders of Nautilus Biotechnology, Inc.?
By the share each holder's latest filing reports, the largest holders of Nautilus Biotechnology, Inc. on this page are Parag Mallick (17.6%) and Sujal Patel (16.3%).
When did Parag Mallick buy into Nautilus Biotechnology, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Parag Mallick on this page is the Schedule 13D/A, filed 2026-03-04, reporting 17.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Nautilus Biotechnology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.